Company intelligence / Profile preview
Regenerative Arthritis and Bone Medicine
Hillsborough, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
RABOME has received FDA approval to begin Phase 1 clinical trials evaluating the safety of its lead compound (LLP2A-alendronate) for osteonecrosis, with other indications in preclinical and translational stages. The technology directs mesenchymal stem cells to bone to enhance bone formation and healing.
- Therapeutic areas
- EndocrinologyRheumatologyOther
- Modalities
- Small moleculeSynthetic oligonucleotide
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
University of California, Davis
Beyond the preview
Go deeper on Regenerative Arthritis and Bone Medicine.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Regenerative Arthritis and Bone Medicine.